Global epidemiology of alcohol-associated liver disease in adolescents and young adults.
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
03 Jun 2024
03 Jun 2024
Historique:
revised:
10
05
2024
received:
19
04
2024
accepted:
22
05
2024
medline:
3
6
2024
pubmed:
3
6
2024
entrez:
3
6
2024
Statut:
aheadofprint
Résumé
The objective of the study was to analyse the prevalence, incidence, and death of alcohol-associated liver disease (ALD) among adolescents and young adults globally, continentally, and nationally, focusing on trends over time. The study analysed data from the Global Burden of Disease (GBD) study between 2000 and 2019. It examined ALD's prevalence, incidence, and death in adolescents and young adults aged 15-29, segmented by region, nation, and sociodemographic index. The analysis utilised Joinpoint regression modelling to calculate the annual per cent change (APC) in the rate of these parameters over time. In 2019, there were 281,450 ALD prevalences, 18,930 incidences, and 3190 deaths among adolescents and young adults globally. From 2000 to 2019, the age-adjusted prevalence rate per 100,000 increased in the 25-29 age group (APC: +0.6%, p = 0.003), remained stable among ages 20-24 (p = 0.302) and ages 15-19 (p = 0.160). Prevalence increased significantly from age 15-19 to 20-24 (19-fold increase) and from age 20-24 to 25-29 (2.5-fold increase). ALD prevalence rates increased in all age groups in adolescents and young adults in Africa and the Eastern Mediterranean region. Around three-quarters of countries and territories experienced an increase in ALD incidence rates in young adults. Over two decades, the burden of ALD among adolescents and young adults has increased globally. The study emphasises the importance of public health policies aimed at reducing alcohol consumption and preventing ALD among younger populations.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
The objective of the study was to analyse the prevalence, incidence, and death of alcohol-associated liver disease (ALD) among adolescents and young adults globally, continentally, and nationally, focusing on trends over time.
METHODS
METHODS
The study analysed data from the Global Burden of Disease (GBD) study between 2000 and 2019. It examined ALD's prevalence, incidence, and death in adolescents and young adults aged 15-29, segmented by region, nation, and sociodemographic index. The analysis utilised Joinpoint regression modelling to calculate the annual per cent change (APC) in the rate of these parameters over time.
RESULTS
RESULTS
In 2019, there were 281,450 ALD prevalences, 18,930 incidences, and 3190 deaths among adolescents and young adults globally. From 2000 to 2019, the age-adjusted prevalence rate per 100,000 increased in the 25-29 age group (APC: +0.6%, p = 0.003), remained stable among ages 20-24 (p = 0.302) and ages 15-19 (p = 0.160). Prevalence increased significantly from age 15-19 to 20-24 (19-fold increase) and from age 20-24 to 25-29 (2.5-fold increase). ALD prevalence rates increased in all age groups in adolescents and young adults in Africa and the Eastern Mediterranean region. Around three-quarters of countries and territories experienced an increase in ALD incidence rates in young adults.
CONCLUSION
CONCLUSIONS
Over two decades, the burden of ALD among adolescents and young adults has increased globally. The study emphasises the importance of public health policies aimed at reducing alcohol consumption and preventing ALD among younger populations.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
Hoel S, Magne Eriksen B, Breidablik HJ, Meland E. Adolescent alcohol use, psychological health, and social integration. Scand J Public Health. 2004;32(5):361–367.
Wang C, Hipp JR, Butts CT, Jose R, Lakon CM. Peer influence, peer selection and adolescent alcohol use: a simulation study using a dynamic network model of friendship ties and alcohol use. Prev Sci. 2017;18(4):382–393.
Obray JD, Landin JD, Vaughan DT, Scofield MD, Chandler LJ. Adolescent alcohol exposure reduces dopamine 1 receptor modulation of prelimbic neurons projecting to the nucleus accumbens and basolateral amygdala. Addict Neurosci. 2022;(100044):4.
TEAM W. A focus on adolescent substance use in Europe, central Asia and Canada. Health behaviour in school‐aged children international report from the 2021/2022 survey. Health Behaviour in School‐aged Children (HBSC). 2024;3.
Crews FT, Vetreno RP, Broadwater MA, Robinson DL. Adolescent alcohol exposure persistently impacts adult neurobiology and behavior. Pharmacol Rev. 2016;68(4):1074–1109.
Bonomo YA, Bowes G, Coffey C, Carlin JB, Patton GC. Teenage drinking and the onset of alcohol dependence: a cohort study over seven years. Addiction. 2004;99(12):1520–1528.
Lee E, Navadurong H, Liangpunsakul S. Epidemiology and trends of alcohol use disorder and alcohol‐associated liver disease. Clin Liver Dis. 2023;22(3):99–102.
Meza V, Arnold J, Díaz LA, Ayala Valverde M, Idalsoaga F, Ayares G, et al. Alcohol consumption: medical implications, the liver and beyond. Alcohol Alcohol. 2022;57(3):283–291.
Danpanichkul P, Wattanachayakul P, Duangsonk K, Ongsupankul S, Sripusanapan A, Uawithya E, et al. The burden of alcohol‐related cardiovascular complications in young and middle‐aged adults: rising burden of atrial fibrillation and hypertensive heart disease. Acta Cardiol. 2024;1–8. Online ahead of print.
Danpanichkul P, Aboona MB, Sukphutanan B, Kongarin S, Duangsonk K, Ng CH, et al. Incidence of liver cancer in young adults according to the global burden of disease database 2019. Hepatology. 2024;1–2. Online ahead of print.
Danpanichkul P, Ng CH, Tan DJH, Wijarnpreecha K, Huang DQ, Noureddin M, et al. The global burden of alcohol‐associated cirrhosis and cancer in young and middle‐aged adults. Clin Gastroenterol Hepatol. 2024;1–2. Online ahead of print.
Singal AK, Mathurin P. Diagnosis and treatment of alcohol‐associated liver disease: a review. JAMA. 2021;326(2):165–176.
Udesen CH, Hviid SS, Becker U, Tolstrup JS. Alcohol‐related mortality in 15‐24‐year‐olds in Denmark (2010‐2019): a nationwide exploratory study of circumstances and socioeconomic predictors. Lancet Reg Health Eur. 2023;29:100620.
Han S, Yang Z, Zhang T, Ma J, Chandler K, Liangpunsakul S. Epidemiology of alcohol‐associated liver disease. Clin Liver Dis. 2021;25(3):483–492.
Osna NA, Donohue TM Jr, Kharbanda KK. Alcoholic liver disease: pathogenesis and current management. Alcohol Res. 2017;38(2):147–161.
Hartmann P, Zhang X, Loomba R, Schnabl B. Global and national prevalence of nonalcoholic fatty liver disease in adolescents: an analysis of the global burden of disease study 2019. Hepatology. 2023;78(4):1168–1181.
Indolfi G, Easterbrook P, Dusheiko G, Siberry G, Chang MH, Thorne C, et al. Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019;4(6):466–476.
Danpanichkul P, Ng CH, Muthiah MD, Duangsonk K, Kongarin S, Srisurapanont K, et al. Metabolic syndrome and metabolic dysfunction‐associated Steatotic liver disease in premenopausal women: global trends and projections to 2040. Mayo Clin Proc. 2024;1–4.
Diseases GBD Injuries C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990‐2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1204–1222.
Paik JM, Golabi P, Younossi Y, Srishord M, Mishra A, Younossi ZM. The growing burden of disability related to nonalcoholic fatty liver disease: data from the global burden of disease 2007‐2017. Hepatol Commun. 2020;4(12):1769–1780.
Danpanichkul P, Ng CH, Muthiah MD, Duangsonk K, Yong JN, Tan DJH, et al. The silent burden of non‐alcoholic fatty liver disease in the elderly: a global burden of disease analysis. Aliment Pharmacol Ther. 2023;58(10):1062–1074.
Danpanichkul P, Ng CH, Muthiah M, Suparan K, Tan DJH, Duangsonk K, et al. From shadows to spotlight: exploring the escalating burden of alcohol‐associated liver disease and alcohol use disorder in young women. Am J Gastroenterol. 2023;119:893–909.
Wu XN, Xue F, Zhang N, Zhang W, Hou JJ, Lv Y, et al. Global burden of liver cirrhosis and other chronic liver diseases caused by specific etiologies from 1990 to 2019. BMC Public Health. 2024;24(1):363.
Paik JM, Kabbara K, Eberly KE, Younossi Y, Henry L, Younossi ZM. Global burden of NAFLD and chronic liver disease among adolescents and young adults. Hepatology. 2022;75(5):1204–1217.
Liu Y, Sun Z, Wang Q, Wu K, Tang Z, Zhang B. Contribution of alcohol use to the global burden of cirrhosis and liver cancer from 1990 to 2019 and projections to 2044. Hepatol Int. 2023;17(4):1028–1044.
Gillis D, Edwards BPM. The utility of joinpoint regression for estimating population parameters given changes in population structure. Heliyon. 2019;5(11):e02515.
Zhang Y, Liu J, Han X, Jiang H, Zhang L, Hu J, et al. Long‐term trends in the burden of inflammatory bowel disease in China over three decades: a joinpoint regression and age‐period‐cohort analysis based on GBD 2019. Front Public Health. 2022;10:994619.
Ma C, Bovet P, Yang L, Zhao M, Liang Y, Xi B. Alcohol use among young adolescents in low‐income and middle‐income countries: a population‐based study. Lancet Child Adolesc Health. 2018;2(6):415–429.
Idalsoaga F, Kulkarni AV, Mousa OY, Arrese M, Arab JP. Non‐alcoholic fatty liver disease and alcohol‐related liver disease: two intertwined entities. Front Med (Lausanne). 2020;7:448.
Li M, Xie W. Are there all‐cause mortality differences between metabolic dysfunction‐associated steatotic liver disease subtypes? J Hepatol. 2024;80(2):e53‐e4.
Díaz LA, Idalsoaga F, Fuentes‐López E, Márquez‐Lomas A, Ramírez CA, Roblero JP, et al. Impact of public health policies on alcohol‐associated liver disease in Latin America: an ecological multinational study. Hepatology. 2021;74(5):2478–2490.
Leal‐López E, Moreno‐Maldonado C, Inchley J, Deforche B, van Havere T, van Damme J, et al. Association of alcohol control policies with adolescent alcohol consumption and with social inequality in adolescent alcohol consumption: a multilevel study in 33 countries and regions. Int J Drug Policy. 2020;84:102854.
Diaz LA, Fuentes‐Lopez E, Idalsoaga F, Ayares G, Arnold J, Ayala‐Valverde M, et al. Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes. J Hepatol. 2023;80:1–2.
Ferreira‐Borges C, Parry CD, Babor TF. Harmful use of alcohol: a shadow over sub‐Saharan Africa in need of workable solutions. Int J Environ Res Public Health. 2017;14(4):6–7.
Mkuu RS, Barry AE, Swahn MH, Nafukho F. Unrecorded alcohol in East Africa: a case study of Kenya. Int J Drug Policy. 2019;63:12–17.
Delirrad M, Mohammadi AB. New methanol poisoning outbreaks in Iran following COVID‐19 pandemic. Alcohol Alcohol. 2020;55(4):347–348.
Ghandour L, Chalak A, el‐Aily A, Yassin N, Nakkash R, Tauk M, et al. Alcohol consumption in the Arab region: what do we know, why does it matter, and what are the policy implications for youth harm reduction? Int J Drug Policy. 2016;28:10–33.
Paik JM, Henry L, Younossi ZM. Reply. Hepatology. 2022;75(6):1663–1664.
Danpanichkul P, Suparan K, Kim D, Wijarnpreecha K. What is new in metabolic dysfunction‐associated steatotic liver disease in lean individuals: from bench to bedside. J Clin Med. 2024;13(1):15–16.
Ye F, Zhai M, Long J, Gong Y, Ren C, Zhang D, et al. The burden of liver cirrhosis in mortality: results from the global burden of disease study. Front Public Health. 2022;10:909455.
Paik JM, Henry L, Younossi ZM. Nonalcoholic fatty liver disease mortality may not be decreasing: a need for careful interpretation of GBD 2019 estimates of liver deaths. Cell Metab. 2023;35(7):1087–1088.
Veracruz N, Gish RG, Cheung R, Chitnis AS, Wong RJ. Global trends and the impact of chronic hepatitis B and C on disability‐adjusted life years. Liver Int. 2022;42(10):2145–2153.
Sindelar HA, Barnett NP, Spirito A. Adolescent alcohol use and injury. A summary and critical review of the literature. Minerva Pediatr. 2004;56(3):291–309.
Sedarous M, Flemming JA. Culture, stigma, and inequities creating barriers in alcohol use disorder management in alcohol‐associated liver disease. Clin Liver Dis (Hoboken). 2023;21(5):130–133.
Satre DD, Chi FW, Mertens JR, Weisner CM. Effects of age and life transitions on alcohol and drug treatment outcome over nine years. J Stud Alcohol Drugs. 2012;73(3):459–468.
Hagstrom H, Andreasson A. Is teenage heavy drinking more hazardous than we thought? Expert Rev Gastroenterol Hepatol. 2019;13(7):603–605.
Hagström H, Hemmingsson T, Discacciati A, Andreasson A. Alcohol consumption in late adolescence is associated with an increased risk of severe liver disease later in life. J Hepatol. 2018;68(3):505–510.
Moon AM, Curtis B, Mandrekar P, Singal AK, Verna EC, Fix OK. Alcohol‐associated liver disease before and after COVID‐19‐an overview and call for ongoing investigation. Hepatol Commun. 2021;5(9):1616–1621.
Kuntsche E, Kuntsche S, Thrul J, Gmel G. Binge drinking: health impact, prevalence, correlates and interventions. Psychol Health. 2017;32(8):976–1017.
Marlowe N, Lam D, Liangpunsakul S. Epidemic within a pandemic: alcohol‐associated hepatitis and COVID‐19. Alcohol Clin Exp Res. 2023;47(10):1883–1889.
Staufer K, Huber‐Schönauer U, Strebinger G, Pimingstorfer P, Suesse S, Scherzer TM, et al. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non‐alcoholic fatty liver disease. J Hepatol. 2022;77(4):918–930.
Dawson DA, Grant BF, Stinson FS, Chou PS. Another look at heavy episodic drinking and alcohol use disorders among college and noncollege youth. J Stud Alcohol. 2004;65(4):477–488.
Ting PS, Lin WT, Huang CK, Lin HY, Tseng TS, Chen PH. Exclusive liquor and cocktail consumption is associated with at‐risk fibrosis among nonheavy alcohol users with metabolic dysfunction‐associated steatotic liver disease. Alcohol Clin Exp Res (Hoboken). 2024;48(1):88–97.